Skip to main content
. 2018 Aug 13;9:883. doi: 10.3389/fphar.2018.00883

FIGURE 7.

FIGURE 7

Effects of Sy-HPBCD and Sy-RAMEB complexes on TGF-β1/Smad signaling pathway. (A) RT-PCR analysis of TGF-β1 gene level. ∗∗∗p < 0.001 compared to control; ###p < 0.001 compared to CCl4 group; +++p < 0.001 compared to CCl4 control group; ˆp < 0.05 compared to CCl4/Sy group; ˆˆˆp < 0.001 compared to CCl4/Sy group. (B) Immunohistochemical expression of TGF-β1 in experimental livers. (a) Control group, (b) CCl4-treated group, (c) CCl4-control group, (d) CCl4 and Sy-RAMEB co-treated group, (e) CCl4 and Sy-HPBCD co-treated group, (f) CCl4 and free Sy co-treated group; RT-PCR analysis of Smad 2 (C), Smad 3 (D), and Smad 7 (E) gene levels. ∗∗∗p < 0.001 compared to control; #p < 0.05 compared to CCl4 group; ##p < 0.01 compared to CCl4 group; ###p < 0.001 compared to CCl4 group; +++p < 0.001 compared to CCl4 control group; ˆˆp < 0.01 compared to CCl4/Sy group; ˆˆˆp < 0.001 compared to CCl4/Sy group. (F) Immunohistochemical expression of Smad 2/3 in experimental livers. (a) Control group, (b) CCl4-treated group, (c) CCl4-control group, (d) CCl4 and Sy-RAMEB co-treated group, (e) CCl4 and Sy-HPBCD co-treated group, (f) CCl4 and free Sy co-treated group.